Shots:

• The CALAVI program involves assessing of Calquence + BSC vs BSC as monothx. in patients hospitalized with respiratory complications of COVID-19- but not on assisted ventilation. The studies are being conducted in the US and outside the US including the EU- Japan and South America
• The drug demonstrated the clinical improvement in peer-reviewed case series of 19 hospitalized patients with COVID-19 and hypoxia and/or inflammation. Results were published in Science Immunology
• Calquence is a BTK inhibitor- act by inhibiting its activity and has received the US FDA approval for hematological malignancies

Click here to read full press release/ article 

Ref: AstraZeneca | Image: Twitter